Loomis, Sayles & Company
XENE icon

Loomis, Sayles & Company’s Xenon Pharmaceuticals XENE Stock Holding History

Loomis, Sayles & Company’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.8M Sell
527,273
-37,624
-7% -$2.09M 0.04% 177
2026
Q1 		$32.8M Sell
564,897
-47,135
-8% -$2.17M 0.04% 153
2025
Q4 		$27.4M Sell
612,032
-28,594
-4% -$1.2M 0.03% 188
2025
Q3 		$25.7M Sell
640,626
-16,539
-3% -$583K 0.03% 201
2025
Q2 		$20.6M Sell
657,165
-15,846
-2% -$517K 0.03% 239
2025
Q1 		$22.6M Sell
673,011
-14,134
-2% -$537K 0.03% 225
2024
Q4 		$26.9M Sell
687,145
-20,077
-3% -$830K 0.03% 213
2024
Q3 		$27.8M Buy
707,222
+46,964
+7% +$1.89M 0.04% 211
2024
Q2 		$25.7M Sell
660,258
-26,252
-4% -$1.05M 0.04% 216
2024
Q1 		$29.6M Sell
686,510
-21,785
-3% -$1M 0.04% 202
2023
Q4 		$32.6M Sell
708,295
-22,421
-3% -$792K 0.05% 182
2023
Q3 		$25M Sell
730,716
-22,810
-3% -$853K 0.04% 214
2023
Q2 		$29M Sell
753,526
-7,041
-0.9% -$280K 0.05% 196
2023
Q1 		$27.2M Buy
760,567
+83,402
+12% +$3.08M 0.05% 194
2022
Q4 		$26.7M Buy
+677,165
New +$24.7M 0.05% 189

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Loomis, Sayles & Company's XENE Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Xenon Pharmaceuticals (XENE) stake by 6.7% in Q2 2026, selling an estimated $2.09M and leaving 527,273 shares worth $31.8M. The position accounts for 0.04% of the portfolio, ranked #177.

Loomis, Sayles & Company first reported a position in XENE in Q4 2022 and has held it in 15 quarters since. The position peaked at $32.8M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Loomis, Sayles & Company held 527,273 shares of Xenon Pharmaceuticals worth $31.8M as of Q2 2026.
  • Loomis, Sayles & Company sold 37,624 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.09M.
  • Xenon Pharmaceuticals made up 0.04% of Loomis, Sayles & Company's portfolio in Q2 2026, its #177 holding.
  • Loomis, Sayles & Company first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Loomis, Sayles & Company's Xenon Pharmaceuticals position peaked at $32.8M in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.